SUMMARY
para-aminosalicylic acid (PAS) is one of antimycobacterial drugs currently used for multidrug resistant tuberculosis. Although it has been in clinical use for over 60 years its mechanism(s) of action remains elusive. Here we report that PAS is a prodrug targeting dihydrofolate reductase (DHFR) through an unusual and novel mechanism of action. We provide evidences that PAS is incorporated into the folate pathway by dihydropteroate synthase (DHPS) and dihydrofolate synthase (DHFS) to generate a hydroxyl-dihydrofolate antimetabolite, which in turn inhibits DHFR enzymatic activity. Interestingly, PAS is recognized by DHPS as efficiently as its natural substrate para-amino benzoic acid (pABA). Chemical inhibition of DHPS or mutation in DHFS prevents the formation of the antimetabolite, thereby conferring resistance to PAS. In addition, we identified a bifunctional enzyme (RibD), a putative functional analogue of DHFR in a knockout strain. This finding is further supported by the identification of PAS resistant clinical isolates encoding a RibD over-expression mutations displaying cross-resistance to genuine DHFR inhibitors. Our findings reveal that a metabolite of PAS inhibits DHFR in the folate pathway. RibD was shown to act as a functional analogue of DHFR and as for DHFS both were shown to be associated in PAS-resistance in laboratory strains and clinical isolates.
Mycobacterium tuberculosis (Mtb) 1 , a human pathogen causing tuberculosis (TB), claims 1.2 to 1.5 million lives each year, and it is estimated that one third of the global population is latently infected by the bacilli (1). With the alarming rise of multidrug-resistant tuberculosis, there is an urgent need for new anti-tuberculosis agents to combat the disease (2) . Understanding the molecular mechanism(s) of action and resistance of current drugs will provide new perspectives and approaches for drug discovery. Para-aminosalicylic acid (PAS) is one of the first antituberculosis agents found to be effective in the 1940s (3) . Though PAS has been widely used clinically its precise mode of action remains largely speculative (4) (5) (6) . The structural similarity between PAS and para-aminobenzoic acid (pABA) has led to the speculation that it might inhibit dihydropteroate synthase (DHPS) in the folate biosynthetic pathway. This speculation is founded on the well-studied mechanism of action of sulfonamides, another group of pABA structural analogues. However, unlike the sulfonamides, PAS has been shown not to be an inhibitor of DHPS (4) . Nevertheless, mutations within the thymidylate-synthase gene thyA have been associated with resistance to PAS in Mtb (7), suggesting that PAS may interfere with the folate pathway through an unknown mechanism. Recently, Chakraborty et al demonstrated that PAS acts as an alternative substrate for folate metabolism in Mtb. However, the specific site of action in the folate pathway that results in growth inhibition remains to be elucidated (8) . The folate pathway generates tetrahydrofolate in prokaryotes and eukaryotes, which is a ubiquitous one-carbon carrier involved in the biosynthesis of purine, thymidine, glycine, methionine and panthotenate. In bacteria, tetrahydrofolate is also required for the synthesis of formylmethionyl tRNA fmet , which is essential for the initiation of protein synthesis. In the folate pathway, DHPS catalyzes the condensation of pABA and 6-hydroxymethyl-7,8-dihydropterin pyrophosphate into 7,8-dihydropteroate, which is then converted by the dihydrofolate synthase (DHFS) into dihydrofolate and reduced to generate the cofactor tetrahydrofolate by the enzyme dihydrofolate reductase (DHFR). DHFR is the target of several important anticancer and antibacterial drugs. For example, methotrexate targets human DHFR and is used as an anticancer drug, whereas both trimethoprim and pyrimethamine are inhibitors of bacterial and protozoal DHFR (9) . WR99210 is another potent DHFR inhibitor and anti-malarial whose clinical development was terminated due to unacceptable side effects (10) . Interestingly, WR99210 is also a potent inhibitor of DHFR and growth inhibitor in Mtb (11) 
EXPERIMENTAL PROCEDURES
Strains and growth conditions-Mtb H37Rv and M. bovis BCG Pasteur strains and their derivatives were maintained in Middlebrook 7H9 broth medium supplemented with 0.2 % glycerol, 0.05 % Tween 80 and 10 % ADS supplement or Middlebrook 7H11 Agar. Culture media were supplemented with hygromycin (50 μg/ml) or kanamycin (25 μg/ml) when necessary.
Drug susceptibility testing-Bacterial drug susceptibility was determined in 7H9 medium as previously described (12) . Briefly, compounds dissolved in 90% DMSO were twofold serial-diluted in duplicates and spotted in 96-well clear plates, resulting in 10 to 12 dilutions of each compound. A volume of 200 µl of Mtb or BCG culture (final OD 600 =0.02) was added to each well, and the assay plates were incubated at 37°C for 5 days. OD 600 values were recorded using a SpetraMax M2 spectrophotometer, and minimum inhibition concentration curves were plotted using Graph Pad Prism 5 software.
Protein purification and analysis-Mtb
H37Rv dfrA, folP (DHPS) and ribD were expressed as 6×His-tagged proteins in E. coli BL21 as previously described and purified by standard procedures (13) . Proteins were analysed with Western blot. Antibody against RibD was raised in rabbits against keyhole limpet haemocyanin-conjugated peptides (RibD, QRQHRQARGQSEVP) by GenScript. The antibodies were affinity purified by using specific peptides as ligands. Antibody against ClpC1 (14) was used as an internal control.
DHFR enzymatic assay-The DHFR enzymatic assay utilizes a tetrazolium dye, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetazolium, inner salt (MTS). Briefly, 2µL of test compound in 90% (v/v) DMSO was added into 96-well plates to incubate with 50 µL of 60 nM DHFR for 30 minutes at room temperature. Then 50 µl of 200µM NADPH was added and incubated for another 10 minutes. The enzymatic reaction was started by adding 100 µL of a mixture containing 10µM dihydrofolate (5µM final concentration) and 300µM MTS (150µM final concentration) diluted in DHFR assay buffer (100mM HEPES, pH7.5 + 50mM potassium chloride + 0.05% CHAPS). The reaction was monitored at an absorbance of 490 nm with kinetic reading for 10 min. For the DHFR enzymatic assay with CLFT, bacterial cultures were grown to an OD 600 of ~ 0.6 in 7H9 media, and antibiotics were added at concentrations of tenfold higher than the MIC 50 achieved with drug susceptibility testing. Cultures were shaken at 60 rpm for varying periods as indicated. Bacterial cells were pelleted and washed once with PBS + 0.05% tween 80. The pellet was re-suspended with 1.5 ml DHFR enzymatic assay buffer. The cells were then broken using 0.1mm glass beads with Precellys 24 (Bertin technologies), and cell lysates were collected after centrifugation. Samples were normalized by measuring protein concentration and then passed through a 10kD cut-off membrane to remove the native DHFR protein. The flow through (CLFT) was then used in the DHFR enzymatic assay. To perform the assay, 10 µl 300nM DHFR was mixed with 90 µl bacterial lysates and incubated at room temperature for 30 min, and 50 µl 20 µM NADPH was then added and kept at room temperature for another 10 min. Fifty microliters of 20µM DHF/600 µM MTS mixture in DHFR assay buffer was added to start the reaction.
DHPS enzymatic assay and identification of hydroxyl-7,8-dihydropteroate by LC/MSMS-
The incorporation of PAS into the folate pathway was examined by DHPS assay as previously described (15) . Pyrophosphate released by the DHPS reaction is cleaved into monophosphate by addition of inorganic pyrophosphatase to allow the formation of a green complex in the presence of Malachite Green and molybdate. Briefly, 6-hydroxymethyl-7,8-dihydropterinpyrophosphate (H2PtPP) (30 μM), purified recombinant Mtb DHPS (0.6 ug) and inorganic pyrophosphatase (0.1 U/mL) were incubated with various amounts of pABA or PAS (0, 2, 4, 8, 16, 32, 64 and 128 μM) in 20 mM Tris-HCl (pH 8.8), 200 mM NaCl, 5 mM MgCl2, 1 mM dithiotreitol in 500 μL at 37 °C for 30 min. After reaction, 100 μL of sample was transferred to 96 well-plate and 20 μL of Malachite Green Assay solution was added. All further steps were carried out according to the manufacturer's protocol for the Malachite Green Assay. Sample from DHPS reaction was used for analysis by a triple quadruple Quattro Premier™ mass spectrometer (Waters, Milford, MA), with electrospray ionization (ESI). Instruments were controlled by Masslynx software (Version 4.0, Waters, Milford, MA). In brief, sample aliquots from DHPS reaction were extracted with acetonitrile. After the removal of proteins by centrifugation at 13,200rpm for 10min at 4 M the supernatant was subjected to HPLC separation with tandem mass spectrometric detection. The mobile phases were (A) water with 0.1% of formic acid and (B) acetonitrile with 0.1% of formic acid at a flow rate of 0.4mL/min. The LC conditions were 5% B at 0min, a linear gradient from 5 to 50% B over 0.5min, held at 50% for 0.25min, then ramped from 50 to 95% over 0.25min, followed by 95% B for 0.75min and back to 5% B over 0.25min, then held at 5% B for the remaining 0.75min. Whole-Genome Sequencing. Whole-genome sequencing was performed as previously described (16) .
Mutant construction and gene overexpression-Disruption of mycobacterial dfrA gene was obtained by allelic exchange as described previously (17) . The mycobacterial mutant was constructed by using a modified plasmid pYUB854. Briefly, a sacB-lacZ cassette was excised from the pGOAL17 plasmid (18) and ligated into the PacI site of pYUB854. About 1kb flanking sequences of the gene of interest were cloned into the derivative plasmid on each side of the hygromycin cassette. The resulting plasmid was introduced into mycobacterial cells by electroporation. Deletion mutants were confirmed by PCR or Southern blotting. For gene overexpression in mycobacterium, the genes of interest were amplified and cloned into plasmid pMV262 (19) . The constructs were then electroporated into mycobacterial strains. Southern blot analysis-Bacterial genomic DNA was digested with PvuII with restriction endonuclease. Southern blotting was performed with the DIG DNA labelling kit, DIG wash and block buffer set, and BT/BCIP stock solution (Roche Diagnostics). Transfers of DNA to nylon membranes, hybridization and visualization were as recommended by the manufacturer's protocol.
RESULTS
Overexpression of dfrA leads to PAS resistance in Mtb-Since the folate pathway is known to be associated with the mechanism of PAS resistance, we tested whether the overexpression of the key enzymes DHFS (encoded by folC) and DHFR (dfrA) would result in PAS resistance. Mtb H37Rv growth was inhibited by PAS with a minimum inhibition concentration (MIC 50 ) of 0.4 M. H37Rv overexpressing dfrA was fully resistant to PAS, with no inhibition observed at PAS concentrations up to 100 M. Conversely, overexpression of folC had no impact on the susceptibility of H37Rv to PAS (Fig. 1A) . These results suggested that DHFR is a potential target of PAS. However, in an in vitro enzymatic assay, PAS did not show any inhibition of recombinant Mtb DHFR (rDHFR), whereas the known DHFR inhibitor WR99210 inhibited rDHFR as expected (Fig. 1B) .
DHFR is inhibited by PAS-treated mycobacterial cell lysates-The observation that PAS did not inhibit DHFR in vitro led us to speculate that PAS might be a prodrug that requires metabolic activation to manifest its inhibitory effect. To test this hypothesis, we made an attempt to bioactivate PAS in mycobacteria. M. bovis BCG was treated with PAS for 3 hours and the cell lysate was isolated, normalized to the protein concentration, and passed through a 10kD cut-off membrane to remove any DHFR protein produced by mycobacterial cells. The cell lysate flowthrough (CLFT) was then used as a potential source of bioactivated PAS to examine the inhibition of rDHFR enzymatic activity. CLFT from PAS-treated cells significantly inhibited rDHFR activity. In contrast, CLFT from streptomycin-treated cells did not show any inhibitory effect (Fig. 2A) . Similar results were obtained in Mtb H37Rv (Fig. 2B) . Intracellular activation of PAS was proven to be timedependent, with maximum rDHFR inhibition (~60%) observed following 6 hours of PAS treatment prior to CLFT isolation and testing in the enzymatic assay (Fig. 2C) . These results suggest that PAS is activated within mycobacterial cells and that its bioconversion product inhibits DHFR.
Since PAS is structurally similar to pABA, the natural substrate of DHPS, we hypothesized that PAS might be incorporated into the folate pathway by competing with pABA in the reaction catalyzed by DHPS, the product of which is further processed by DHFS to generate hydroxyl-dihydrofolate (Fig. 3) . This derivative could be the active form of PAS, which would subsequently interact with DHFR to inhibit its enzymatic activity and eventually bacterial growth (Fig. 3) . A prediction based on this hypothesis is that exogenous addition of pABA should reduce PAS-mediated growth inhibition of Mycobacterium and the formation of the PAS-derived antimetabolite. Indeed, the PAS-mediated mycobacterial growth-inhibition in Mtb (20) and M. bovis BCG was alleviated in the presence of pABA (Fig. 2D) . In addition, the formation of the PAS-derived antimetabolite was significantly reduced in the presence of pABA (Fig. 2E) . Thus these results indicate that PAS is activated within mycobacterial cells and competes with pABA for its bioactivation, the product of which targets DHFR.
PAS act as a substrate of DHPS and is incorporated into the folate pathway-We next sought to test whether PAS is recognized as a direct substrate by DHPS. A nonradioactive enzymatic assay for the recombinant mycobacterial DHPS reveled that PAS is indeed recognized as a substrate by DHPS, and the affinity of PAS to DHPS was comparable to that of pABA in the presence of the cofactor 6-hydroxymethyl-7,8-dihydropterinpyrophosphate (H 2 PtPP). Under our experimental conditions, pABA had a Michaelis constant (K m ) of 11.4 ± 0.1 for DHPS, whereas PAS had a K m of 17.7 ± 0.1 (Fig. 4, A and B) . The condensation of PAS with the DHPS co-factor H 2 PtPP should theoretically lead to the synthesis of hydroxyldihydropteroate. The mixture reactions were then analyzed by LC/MSMS. A peak at 329 (m/z) corresponding to hydroxyldihydropteroate was identified from the reaction mixture by the Q1 full scan (Fig. 4C) , which is not observed with the reaction lacking DHPS. The ion was further fragmented into two peaks at 176 (m/z) and 151 (m/z) corresponding to H 2 PtPP and PAS, respectively in Q3 scan (Fig. 4D) . The chromatograms monitoring this ion demonstrated a single peak (Fig. 4E) , suggesting that hydroxyldihydropteroate was indeed produced by DHPS with PAS and H 2 PtPP as substrate. These data showed that PAS can be incorporated into the folate pathway and bioactivated into an antimetabolite at the level of DHPS.
Enzymes from the folate pathway are required for PAS bioactivation-According to our proposed antimetabolite model for the PAS mechanism of action (Fig. 3) , the activation of PAS requires functional DHPS and DHFS. Any interruption of their function should therefore impair hydroxyl-dihydrofolate synthesis, and thus give rise to PAS resistance. To test this hypothesis, we first examined whether inhibition of DHPS would result in PAS resistance. Depletion of DHPS fails to phenocopy treatment with sulfonamides, a presumed inhibitor of the enzyme probably because DHPS is present in considerable excess or the activity of the enzyme has to be reduced by approximately 99% to prevent growth (21) (22) (23) (24) . We thus treated mycobacterium with PAS in the presence of different concentration of sulfonamide, and bacterial growth was measured after 5 days of treatment. In agreement with our hypothesis, addition of sulfathiazole to bacterial cultures indeed decreased Mtb susceptibility to PAS, with complete neutralization of PAS-mediated growth inhibition at sulfathiazole concentrations above 40 µM (Fig. 5A) . Similar results were observed with other sulfonamides (data not shown). Furthermore, addition of sulfathiazole to PAS-treated mycobacterial cultures suppressed the inhibition of rDHFR by CLFT (Fig. 5B) .
The other enzyme predicted to be required for generating the proposed hydroxyldihydrofolate is DHFS (folC). Since there are no known DHFS inhibitors, we resorted to a genetic approach to demonstrate the requirement of DHFS for PAS activation. By screening for spontaneous PAS resistant mutants, we isolated one Mtb mutant (folCE40A) displaying high-level resistance to PAS (Fig. 5C ). This mutant harbored a mutation in folC resulting in a substitution of DHFS residue Lys40 by Ala. Lys40 is located in a mobile loop of both Mtb and E. coli DHFS and has been shown to be important for pteroate binding in E. coli (25, 26) . Complementation of folCE40A with wild-type folC restored PAS susceptibility to wild-type levels (Fig. 5C ), confirming that a mutation in the folC gene is associated with resistance to PAS. Collectively, these results indicate that PAS-mediated growth inhibition is DHPS and DHFS dependent.
RibD is a putative functional analogue of DHFR-To date, the isolation of spontaneous PAS resistant mutants has not revealed mutations in DHFR (7). This may suggest that the fitness cost of a mutation in DHFR is higher than for any other genes of the folate pathway, at least in vitro. We thus set out to select spontaneous Mtb mutants resistant to a specific DHFR inhibitor. In the context of a targetbased drug discovery project, we synthesized a series of WR99210-analogues, one of which (NITD344) inhibited both DHFR enzymatic activity and Mtb growth (Fig. 6, A and B) . Analysis of 20 spontaneous Mtb mutants resistant to the DHFR inhibitor NITD344 demonstrated no mutations in dfrA. To get an insight into the genetic determinant of the resistance to NITD344, the whole genome of the NITD344 resistant mutant Mtb R7 was sequenced. The results revealed a G to A substitution located 11bp upstream of the translational start codon of RibD (Rv2671), causing increased RibD expression (Fig. 6C) . Although RibD is annotated as a riboflavin biosynthesis protein, its C-terminal reductase domain shares strong sequence similarities with dihydrofolate reductases (27, 28) (data not shown). Since overexpression of RibD caused resistance to a specific DHFR inhibitor, we tested whether it is also confered resistance to PAS. Interestingly, Mtb R7 was cross-resistant to PAS (Fig. 6, D and E) . Moreover, overexpression of RibD into Mtb also conferred resistance to PAS (Fig. 6, B & C) . In contrast, overexpression of another classical riboflavin biosynthesis protein RibG did not affect mycobacterial growth inhibition by NITD344 or PAS (data not shown). Importantly, 3 out of 30 distinct Mtb clinical isolates (7) resistant to PAS harbored the same regulatory mutation found in the strain Mtb R7, showing that this mutation is associated with PAS resistance in human.
The observation that RibD overexpression confers resistance to a specific DHFR inhibitor led us to speculate that RibD might function as a dihydrofolate reductase when expressed at high level. Through, genetic studies we showed that dfrA is essential (29) . However, the gene could successfully be knocked out in Mtb when RibD was overexpressed from a multi-copy plasmid (Fig. 7, A and B) . These results indicate that RibD, when expressed at high levels, can provide sufficient one-carbon carriers to sustain bacterial survival in the absence of dfrA.
DISCUSSION
The folate biosynthetic pathway is essential in the production of tetrahydrofolate and derivatives required as cofactors in the biosynthesis of purines, thymidylate, serine and methionine (30) . Unlike vertebrates, which utilize exogenous sources of folates, many prokaryotes and protozoa must synthesize these essential cofactors de novo. The folate pathway thus has been targeted for the development of new antibiotics. Nevertheless, none of the enzymes in the folate pathway has conclusively been shown to be the target of current antimycobacterials.
Recently, PAS, an antimycobacterial drug which has been in clinical use for more than 60 years, has been linked to the folate pathway (5). However, its exact molecular target and mechanism(s) of action are still not clear. Here our results indicate that PAS acts as a metabolic precursor which, when incorporated in the folate pathway by DHPS and DHFS, generates a toxic dihydrofolate analog that subsequently poison the folate pathway.
During the synthesis of tetrahydrofolate, DHPS in the folate pathway catalyzes the condensation of pABA and 6-hydroxymethyl-7,8-dihydropterin pyrophosphate to form 7, 8-dihydropteroate (31) , which is then used as a substrate of DHFS in the synthesis of DHF. Reduction of dihydrofolate to tetrahydrofolate is carried out in most bacteria and eukaryotes by the enzyme DHFR. Our results support that PAS is mis-incorporated into the folate pathway as a pABA surrogate. Rather than directly inhibiting DHPS as previously speculated (4), PAS is recognized by DHPS as a substrate and converted into hydroxyldihydropteroate. However, the hydroxyldihydropteroate does not block the folate pathway itself. Instead, it functions as a substrate of DHFS in the synthesis of hydroxyldihydrofolate through the incorporation of glutamate. The close structural analogy between hydroxyl-dihydrofolate and dihydrofolate suggests that these compounds possibly competing for the active site of DHFR (Fig. 3) . The binding of hydroxyl-dihydrofolate to DHFR likely block its enzymatic activity. This leads to a depletion of tetrahydrofolates essential for protein synthesis resulting in inhibition of bacterial growth and death. However, the specific effects of this interaction remain elusive. A proof of principle for this mechanism is to assess the activity of hydroxyldihydrofolate in the rDHFR enzyme assay. However, ours attempt to synthesize hydroxyldihydrofolate was impaired by the production of unstable intermediaries. Noteworthy, consistent with our hypothesis, we demonstrated that PAS was bioactivated into an antimetabolite at the level of DHPS to generate its precursor hydroxyl-dihydropteroate. Moreover, the fact that CLFT from PAS-treated cells inhibits rDHFR as well as that inhibition of DHPS or mutation in DHFS (folC) decreases Mtb susceptibility to PAS further supports our antimetabolite model for the mechanism of action of PAS.
While we have been unable to identify spontaneous mutants resistant to PAS or NITD344 encoding mutations in DHFR (dfrA), polymorphisms in other enzymes of the folate pathway, notably the ThyA (thymidylate synthase) is well known to contribute to PAS resistance (7) in addition of the DHFS and RibD identified in this study. These observations are not at odds with our model of DHFR being a target of a PAS-derived antimetabolite. Treatment of bacteria with PAS inhibits DHFR, resulting in reduction of tetrahydrofolate production. As thymidylate synthase is a major consumer of reduced folates, mutations in thyA are likely to cause a decrease in the utilization of tetrahydrofolate derivatives. Thus more reduced folates become available for other essential one-carbon addition reactions, leading to increased bacterial survival (32) . Mutations in the thyA are permissible likely due to the fact that Mtb encodes ThyX, a highly active functional analogue of thyA which utilizes THF as a carrier of single-carbon groups but not as a cofactor. Mutations in the thyA are found in clinical PAS-resistant isolates but not in the dfrA (7) . Interestingly, RibD provides an additional gene target for PAS resistance of clinical relevance. We found that RibD overexpression replaced the functional activity of dfrA in a knockout dfrA recombinant strain, clearly indicating that RibD either possess DHFR-like activity or is able to catalyze an alternative reaction which complements the classical DHFR. However, RibD is ordinarily present in low concentrations or has poor DHFR activity, thus it cannot completely replace dfrA essential function unless overexpressed. Our findings suggest that in addition to thyA, folC and ribD are candidates for the rapid identification of PAS resistance in clinical studies.
PAS or its metabolite acts as substrate for an essential enzyme. While it does seem possible to have mutations in the activating enzyme DHFS, which no longer catalyze the bioconversion of PAS, most resistance in clinical isolates seem to result from metabolic remodeling of the cell. In other bacteria, drug synergy can occur by inhibition of multiple steps in the folate synthetic pathway, e.g., through the combined use of trimethoprim and sulfonamide drugs (33) . Our results suggest that there are at least two mechanisms to evade killing even by such a combination, either through decreased utilization of folates (thyA mutations) or up-regulation of an alternate pathway (RibD overexpression mutations). On the other hand, such adaptations could well incur significant fitness costs yet to be explored, particularly when growing in the hostile environment of the host.
In conclusion, our results indicate that PAS is a prodrug and it acts as a metabolic precursor which, when incorporated in the folate pathway by DHPS and DHFS, generates a toxic dihydrofolate analog that subsequently inhibits DHFR activity. In this model the antibiotic is converted to an active form intracellularly by a metabolic pathway, but unlike classical prodrugs, it mimics the substrate of an essential enzyme leading to poisoning of the metabolic pathway itself by its bioactivation product. A model of PAS mechanism of action in Mycobacterium. The normal folate pathway is depicted on the left side. As a pABA analogue, PAS is incorporated into the folate pathway by competing with pABA in the reaction catalyzed by DHPS, the product of which is further processed by DHFS to generate hydroxyl-dihydrofolate (right side). This antimetabolite in turn inhibits DHFR activity (denoted by the T bar) and thus blocks the folate pathway (denoted by the cross). 
